Brief: FDA Approves First Oral Carbapenem Therapy For Complicated Urinary Tract Infections
17/06/2026 16:07
BRIEF-FDA Approves First Oral Carbapenem Therapy For Complicated Urinary Tract Infections June 17 (Reuters) - FDA:
FDA APPROVES FIRST ORAL CARBAPENEM THERAPY FOR COMPLICATED URINARY TRACT INFECTIONS
FDA: APPROVED UTEBZI (TEBIPENEM PIVOXIL) TABLETS FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)